Live from the NIH registry
Studies recruiting near Kalamazoo right now
Top 25 of 107 recruiting studies, sorted by proximity — each links to its official registry page
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Ganglioneuroblastoma, Nodular, Neuroblastoma
Phase 3
Interventional 478 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Phase 3
Interventional 474 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: NRG Oncology
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2, Phase 3
Interventional 1,122 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor
Phase 2
Interventional 256 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Children's Oncology Group
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 3
Interventional 486 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: NRG Oncology
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Schizophrenia
Phase 1
Interventional 64 participants sought
Western Michigan University — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Janssen Research & Development, LLC
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
WMU Homer Stryker MD School of Medicine — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Novo Nordisk A/S
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Phase 3
Interventional 286 participants sought
Paragon Health Nephrology Center - Kalamazoo — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Boehringer Ingelheim
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
West Michigan Cancer Center — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Stage III Colon Cancer
Phase 2, Phase 3
Interventional 1,912 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: NRG Oncology
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3
Interventional 94 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: SWOG Cancer Research Network
Mobile Health for Adherence in Breast Cancer Patients
Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma
N/A
Interventional 410 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 1,524 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Lung Non-Small Cell Carcinoma
Phase 2
Interventional 88 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: SWOG Cancer Research Network
Quality of End-of-Life Care for Children With Cancer
Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
N/A
Observational 2,425 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Children's Oncology Group
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 247 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 1, Phase 2
Interventional 960 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: PedAL BCU, LLC
Transcutaneous Electrical Stimulation and Controlled Heat in People With and Without Diabetes
Diabetes, Heat
N/A
Interventional 20 participants sought
Western Michigan University — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Western Michigan University
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Acute Myeloid Leukemia
Phase 3
Interventional 1,186 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Children's Oncology Group
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor
Phase 3
Interventional 1,656 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Children's Oncology Group
Artificial Intelligence to Measure Adherence to Oral Medication
First Episode Psychosis
Phase 4
Interventional 200 participants sought
InterAct of Michigan — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Northwell Health
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Bronson Methodist Hospital — Kalamazoo, Michigan (1.2 mi)
· Sponsor: National Cancer Institute (NCI)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Phase 3
Interventional 5,700 participants sought
Western Michigan University — Kalamazoo, Michigan (1.2 mi)
· Sponsor: Novartis Pharmaceuticals